Dexcom (NSDQ:DXCM) topped expectations on Wall Street this week with its fourth quarter and full-year financial results.
The San Diego, Calif.-based company posted a net loss of -$179.7 million, or -$2.03 per share, on sales of $338 million for the 3 months ended Dec. 31, for sales growth of 52.9% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.